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ABSTRACT
Heat shock transcription factor (HSF1) is a
conserved master regulator that orchestrates the
protection of normal cells from stress.
However, HSF1 also protects abnormal cells and is
required for carcinogenesis. Here, we generate an
highly specific RNA aptamer (iaRNA
HSF1) that
binds Drosophila HSF1 and inhibits HSF1 binding
to DNA. In Drosophila animals, iaRNA
HSF1 reduces
normal Hsp83 levels and promotes developmental
abnormalities, mimicking the spectrum of pheno-
types that occur when Hsp83 activity is reduced.
The HSF1 aptamer also effectively suppresses the
abnormal growth phenotypes induced by constitu-
tively active forms of the EGF receptor and Raf
oncoproteins. Our results indicate that HSF1 con-
tributes toward the morphological development of
animal traits by controlling the expression of mo-
lecular chaperones under normal growth conditions.
Additionally, our study demonstrates the utility of
the RNA aptamer technology as a promising
chemical genetic approach to investigate biological
mechanisms, including cancer and for identifying
effective drug targets in vivo.
INTRODUCTION
HSF1 is a highly conserved transcription factor that
responds to a variety of signals to regulate the expression
of a broad spectrum of target genes (1,2). HSF1 activity in
Drosophila and Saccharomyces cerevisiae is encoded by a
single HSF1 gene; while in mammals and plants multiple
isoforms exist that appear to have specialized functions
(3–6). In response to thermal exposure, HSF1 is respon-
sible for activating the heat shock (HS) response, a highly
conserved mechanism among different kingdoms (7).
During this response, HSF1 activates the expression of a
speciﬁc set of HS genes, resulting in the accumulation of
proteins possessing chaperoning activities that allow or-
ganisms to cope with cellular damage induced by thermal
stress. Additionally, HSF1 activity has been shown to be
important during certain cell and developmental processes
in various organisms. In S. cerevisiae, HSF1 is essential
for cell viability and for vegetative growth (8). Unlike
yeast, animals do not require HSF1 activity for general
cell growth; rather HSF1 is required during speciﬁc devel-
opmental stages. For instance, in Drosophila, HSF1
activity is required for early larval development and
during oogenesis (9); while in Caenorhabditis elegans,
HSF1 has been shown to be required for maintenance of
longevity (10,11). Mammals have evolved multiple HSFs
with specialized functions which appear to play multiple
regulatory roles during development that extend beyond
the HS/stress response (2–5).
Although mouse HSF1 activity is not required for
animal viability, it does protect cells from cellular insults
(4,12,13) and, interestingly, also has been implicated in
cancer as a ‘non-classical oncogene’ (14). Importantly,
HSF1 activity promotes tumor formation and participates
in the maintenance of the transformed phenotype of
cancer cells without affecting the viability of normal cells
(14). Therefore, HSF1 can function to promote cell
survival even under conditions that could potentially
become deleterious to cells, such as development of the
transformed state.
To further understand HSF1 function during animal
development and its role in tumor maintenance, we used
RNA aptamer technology as a chemical–genetic approach
to inhibit HSF1 activity in Drosophila melanogaster.
Aptamers are single-stranded RNA molecules that can
bind with high afﬁnity to speciﬁc molecular surfaces
through ionic, hydrophobic and hydrogen bond inter-
actions. They are isolated from combinatorial libraries
containing  1 10
15 different RNA molecules through
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systematic evolution of ligands by exponential enrichment
(SELEX) (15,16). The large sequence complexity
associated with such a starting library enhances the prob-
ability of isolating speciﬁc and high-afﬁnity aptamer
RNAs to various types of molecular targets, ranging
from single small molecules (17) to distinct functional
domains on a protein (18). Aptamers have also been
used previously in therapies (19,20) and in basic research
(21,22), demonstrating the broad utility of these molecular
inhibitors. Aptamers can not only be selected to bind and
inhibit distinct molecular surfaces with high speciﬁ-
city, they can also be expressed in vivo under tight
genetic control (23) and assert their effect within speciﬁc
cells, tissues or at speciﬁc developmental stages with-
out eliciting an immune response in the targeted
organism (24).
Herein, we report the design, construction and valid-
ation of a potent inhibitory aptamer RNA molecule for
HSF1 (iaRNA
HSF1). This iaRNA
HSF1 contains two HSF1
binding domains engineered from a previously isolated
RNA aptamer that targets the highly conserved HSF1
DNA binding domain-linker region (25). In Drosophila,
we demonstrate that this iaRNA
HSF1 is highly speciﬁc to
HSF1 and can interfere with the HSF1 trans-activa-
tion function under both non-induced and HS condi-
tions in vivo. Because of the broad implication of
increased Hsp levels in diseases, such as human cancer
(14,26–29), we examined the effect of iaRNA
HSF1
under conditions that model cellular transformation in
ﬂies. In Drosophila, HSF1 inhibition by iaRNA
HSF1
suppresses the abnormal phenotypes that are induced by
the expression of gain-of-function mutants of the epider-
mal growth factor receptor (EGFR ellipse mutant)
and Raf oncogenes, and the effects of iaRNA
HSF1 expres-
sion are similar to the usage of Hsp83 loss-of-function
mutants or treatment of ﬂies with the Hsp83 inhibitor
17-allylamino-17-demethoxygeldanamycin (17-AAG), a
frequently used anticancer agent in humans (30).
MATERIALS AND METHODS
Oligonucleotides and other reagents
A single iaRNA
HSF1 unit was constructed in two parts by
extending 50 pmol of each of the following primer sets
(I and II; III and IV) in 100ml using a single round PCR
reaction:
(I) 50-CCGCTCGAGTGACGTTGGCATCGCGATACA
AAATTAAGTTGAACGCGAGTTCTTCGGAAT,
(II) 50-GGCCGGAATTCAAGGAGTATGACGAAGGC
AGTTGAATTCCGAAGAACTCGCGTTCAACTT,
(III) 50-GGCCGGAATTCAACTGCCTTCGGGCATC
GCGATACAAAATTAAGTTGAACGCGAGTT
CTTGGAGGCTCGACGTCT,
(IV) 50-CGCGTCGACGTTTCGTCCTCACGGACTC
ATCAGTAGCGAAACCACATCGCTAGACGT
CGAGCCTCCAAGAACTCG.
Each half of the molecule was puriﬁed by running the
extended products on high-resolution 8% native gel and
extracted from the gel matrix as visualized by
EtBr staining. Then each template was restricted
with EcoR1 (Invitrogen), ligated together, and cloned
into pstBlue-blunt cloning vector (Invitrogen):
pstBlue.iaRNA
HSF1X1 is a coding sequence that contains
two individual (AptHSF1-1) gene upstream of a
self-cleaving hammer-head ribozyme.
Construction of synthetic genes
Repetitive head-to-tail iaRNA
HSF1 genes were created by
sub-cloning iaRNA
HSF1X1 into a Gateway donor vector
(pDONR221.iaRNA
HSF1X1) by lifting the iaRNA
HSF1X1
sequence from pstBlue.iaRNA
HSF1X1 using primers con-
taining the AttB1F and AttB2R Gateway cloning se-
quences (Invitrogen): 50-AAG TTT GTA CAA AAA
AGC AGG CTT CGG ATC CAG AAT TCG TGA TC
and 50-GGG GAC CAC TTT GTA CAA GAA AGC
TGG GTT AGC CTA GGT CGA CG. Because each
iaRNA
HSF1 unit is ﬂanked by the complementary
asymetric Xho1 and Sal1 restriction sites at the 50- and
30-ends, respectively, we can use the general Gateway
cloning strategy to select for correctly ligated tandem
iaRNA
HSF1 repeats (Supplementary Methods S1). In this
method, a single iaRNA
HSF1X1 unit is ﬁrst lifted from
pDONR221.iaRNA
HSF1X1 via PCR and the resulting
amplicon is cut with either Sal1 or Xho1 before the cut
products are combined and ligated together. Using this
scheme, only those products that are in proper head-to-tail
orientation contain the required Gateway AttB sites in the
50- and 30-ends (AttB1F.iaRNA
HSF1X2.AttB2R) needed for
creation of an Gateway compatible Drosophila transform-
ation expression vector, pUAS.iaRNA
HSF1X2. Using the
polymer of two as template and repeating the polymer-
ization strategy creates a polymer of four,
p{UAS.iaRNA
HSF1X4, w+}. Overall, geometric progres-
sion of polymeric length is achieved in each subsequent
round of polymerization.
Drosophila strains
Parental iaRNA
HSF1 animals were created by injecting
Drosophila
w1118 embryos with p{UAS.iaRNA
HSF1X8,
w+} and p{UAS.iaRNA
HSF1X16, w+} transformation
vectors and screening the progeny of F1 females for
animals that contain the mini-white gene when crossed
to a double-balanced CSX ﬂy line containing CyO(2);
TM6(3); Xasta(2,3). Sites of p-element insertions were
determined genetically by continuous backcrossing to the
CSX stock, resulting in homozygous ﬂy lines that con-
tain aptamer genes in various chromosomes:
(i) UAS.iaRNA
HSF1X8(X), (ii) UAS.iaRNA
HSF1X16(X),
(iii) UAS.iaRNA
HSF1X8,16(X), (iv) UAS.iaRNA
HSF1X8(II),
(v) UAS.iaRNA
HSF1X16(II), (vi) UAS.iaRNA
HSF1X8,16(II),
(vii) UAS.iaRNA
HSF1X16(III). To express iaRNA
HSF1,w e
crossed homozygote UAS.iaRNA
HSF1 parentals with
various Gal4 sources purchased from Drosophila Stock
Center (Bloomington): 6983 (Salivary Gland Gal4), 5138
(Ubiquitous tubulin Gal4). Systemic iaRNA
HSF1 expressing
animals were created by isolating F1 females from aptamer
parentals in the second chromosome (UAS.iaRNA
HSF18
and UAS.iaRNA
HSF18,16) mated to 5138 animals.
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and the resulting F2 animals that contained both aptamer
genes and Gal4 protein (UAS.iaRNA
HSF1/CyO;
Tub.Gal4/Sb) were isolated and isogenized to create true
breeding aptamer expressing lines. Other Bloomington
stocks used in this study include: 5693 (Hsp83
e6D
antimorphic mutant), 5743 (Duplication 61F7–F8;
64B10–12). Animals containing the pUAS.eGFP(I) trans-
genes were a kind gift provided by Dr Garcia-Bellido’s
laboratory, and animals expressing the gain of functions
EGFr
Elp and Raf
BT98 mutants were kindly provided by Dr
Marc Therrien’s laboratory.
In vitro binding assays
Internally labeled
32P-UTP iaRNA
HSF1 was transcribed
from an iaRNA
HSF1X1 PCR template containing a 50-T7
promoter using Maxi-script Kit and instructions
(Ambion) and puriﬁed by gel electrophoresis.
Electrophoretic motility shift assays (EMSA) were per-
formed by addition of increasing molar amounts of
puriﬁed GST-HSF1 protein to limiting amounts of
32P-iaRNA
HSF1 (<1nM) using the following binding con-
ditions: 25mM Tris–HCl, 75mM KOAc, 0.5Mm MgCl2,
10% glycerol pH 7.4 and allowing complexes to form for
0.5h at 25 C. The RNA protein complexes were separated
in 6% native gel (3mM Tris–HCl, 200mM glycine,
0.5mM MgCl2). Competition experiments were per-
formed by pre-incubating increasing molar amounts of
cold-iaRNA
HSF1 mixed with T4 kinase labeled Hsp83 or
Hsp70 promoter DNAs to 50nM puriﬁed GST-HSF1
before separating the complexes on 2% native gels (0.5 
TAE, 0.5mM MgCl2) or by ﬁlter binding assays. The
promoter DNA sequences were ampliﬁed from
Drosophila genomic DNA using the following primer
sequences:
Hsp83 449F: 50-ACTTGACTGGGCTTGTAGCAGGTT,
Hsp83+114R: 50-TTCTGGATGCCAGGGATGCAACTT,
Hsp70 200F: 50-TGCCAGAAAGAAAACTCGAGAAA,
Hsp70+64R: 50-CTGCGCTTGTTTGTTTGCTTAGCT.
RNA quantiﬁcation
Total RNA was extracted from whole animals using
Trizol reagent (Invitrogen). Quantiﬁcation of the relative
transcript levels was determined by oligo-dT reverse tran-
scription, followed by real-time PCR analysis (RT–qPCR)
using the following primer sets:
Rp49+141F: 50-CCCAAGGGTATCGACAACAGA,
Rp49+204R: 50-CGATGTTGGGCATCAGATACTG,
18S+417F: 50-TGACGAAAAATAACAATACAGGAC
TCA,
18S+569R: 50-CAGACTTGCCCTCCAATTGG,
iaRNA
HSF1 F: 50-TGGTTTCGCTACTGATGAGTCCGT,
iaRNA
HSF1 R: 50-GCAGTTGAATTCCGAAGAACTCGC,
Hsp70Ab+2155F: GGTCGACTAAGGCCAAAGAGTCTA,
Hsp70Ab+2266R: TCGATCGAAACATTCTTATCAGT
CTCA,
Hsp83+3628F: 50-GCGACCAGTCGAAACAAACAACCA,
Hsp83+3732F: 50-AACTCGGCCGTAGTAAACTCAG,
Hsp26+580F 50-CAAGGTTCCCGATGGCTACA,
Hsp26+667R 50-CTGCGGCTTGGGAATACTGA.
All statistical analyses in this study were calculated using
Student’s t-test.
Immunoﬂuorescent assays of polytene chromosomes
Salivary glands were dissected from third stage instar
larvae in 0.5  Grace’s medium. Chromosomes were
spread, ﬁxed onto slides and immunostained using
antibodies targeting HSF1, GAGA factor (GAF) as
described previously in Schwartz et al. (31).
Morphological studies
Aptamer expressing animals were scored for phenotypic
abnormalities using a dissecting microscope. Here, the
abnormal Drosophila traits were quantiﬁed by screening
a population of aptamer expressing animals (>500 ﬂies)
and determining the number of animals with abnormal
traits in the total population. Pictures were taken using
an 8.0Mb Nikon digital camera mounted onto the
microscope. Quantiﬁcation of morphological
abnormalities was calculated by quantifying abnormal
size or area using the ImageJ software.
Cell culture
iaRNA
HSF1X8 was subcloned into Gateway pDEST48
(Invitrogen) and stable Drosophila S2 cells were selected
by maintaining cells in 6mg/ml Blasticidin reagent.
iaRNA
HSF1 was induced using 0.5mM CuSO4.
iaRNA
HSF1 half-life (t1/2) determination was performed
by treating cells with 0.5mM CuSO4 for 24h before
adding 1mg/ml alpha-amanitin, a potent RNA Pol II in-
hibitor. Upon the addition of amanitin, cells were col-
lected and the total RNA samples were isolated using
the Trizol reagent and protocol. Total iaRNA
HSF1
values were calculated by comparing their relative levels
to 18S RNA levels at speciﬁc time points following
amanitin treatment.
RNAi treatment
Approximately 1 10
6 Drosophila S2 cells were
incubated with 10mg dsRNA targeting HSF1 and Hsp83
for 5 days using genes containing T7 promoter target-
ing each sequence ampliﬁed from Drosophila genomic
DNA:
T7Hsp83+378F: 50-TAATACGACTCACTATAGGGTT
CCATGATCGGTCAGTTCGGTGT,
T7Hsp83 1048R: 50-TAATACGACTCACTATAGGGC
GTACAGCTTGATGTTGTTGCGCT,
T7HSF1 F: 50-GAATTAATACGACTCACTATAGGG
AGAGCCTTCCAGGAGAATGCA,
T7HSF1R: 50-GAATTAATACGACTCACTATAGGG
AGAGCTCGTGGATAACCGGTC.
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Design, construction and validation of the iaRNA
HSF1
expression system
Previously, we isolated an RNA aptamer that binds the
DNA binding domain of Drosophila HSF1 with an
apparent dissociation constant (Kd) of 20–40nM (25).
Because HSF1 is multimeric, we used this aptamer to con-
struct a divalent version that we demonstrate has a several
fold higher afﬁnity, Kd 8nM (Figure 1A–C). This
improved avidity of iaRNA
HSF1 is sufﬁcient to prevent
HSF1 from binding to its natural binding sites on the
Hsp70 and Hsp83 promoters in vitro (Figure 1D and E).
As shown here, increasing the concentrations of HSF1
results in the formation of various protein–DNA
complexes as visualized by the altered electrophoretic
motility (Figure 1D, lanes 2–4). The long HS element
(HSE) of Hsp83 can bind multiple HSF1 trimers, and
the weaker bands of intermediate mobility likely represent
binding of non-saturating amounts HSF1 trimers to this
HSE. These weaker bands and the major shifted band are
all effectively inhibited by increasing amounts of
iaRNA
HSF1 (Figure 1D, compare lanes 5–8 versus 9–12).
To test the effect of iaRNA
HSF1 on HSF1 function in
animals, we generated an aptamer expression system
designed to rapidly produce high levels of nuclear
localized dimeric iaRNA
HSF1 in desired cell types. The
approach was a systematic step-wise variation of that
used by Shi et al. (23). The dimeric iaRNA
HSF was
joined to a hammerhead ribozyme and this unit was
duplicated and the product reduplicated by a
forced-Gateway cloning strategy to generate up to 16 re-
petitive head-to-tail repeats under the control of a
Gal4-activated promoter (Figure 2A and Supplementary
Methods S1). The resulting expression system allows
high-level expression of dimeric aptamer RNAs, because
each repeating aptamer coding unit within a given poly-
meric template is ﬂanked by a self-cleaving hammer-head
ribozyme. Upon transcription of the polymeric template
RNA in a tissue expressing the Gal4 transcription activa-
tor, the hammer-head ribozymes undergo self-cleavage re-
sulting in the release of multiple free functional iaRNAs
from every transcription cycle (23) (Supplementary
Figure S1A). This self-cleavage ensures that the aptamer
RNAs are not polyadenylated and not substrates for
nuclear export; therefore, they should remain localized
within the nucleus. Additionally, the self-ligation activity
of the released form of the hammerhead creates covalently
closed circles that are thought to stabilize and protect the
RNA aptamer from degradation (23).
To test the stability of iaRNA
HSF1 in living cells, we
analyzed the rate of iaRNA
HSF1 decay in stable
Drosophila cells at speciﬁc times following alpha-amanitin
treatment. In these experiments, the iaRNA
HSF1 exhibited
an in vivo half life of  2h (Supplementary Figure S1B).
Finally, to test the production of iaRNA
HSF1 in whole
Drosophila animals, we crossed ﬂies with the
Gal4-regulated polymeric aptamer gene with a line ex-
pressing a tubulin-promoter-driven Gal4 gene. The
iaRNA
HSF1 level is elevated  150-fold over parental
strains that lack Gal4 protein (Supplementary
Figure S1C) demonstrating that the aptamer gene is
regulated by Gal4. Collectively, our results reveal that
this engineered polymeric dimeric aptamer construct has
an improved apparent afﬁnity for HSF1, is stable under
cellular conditions, and can be effectively induced to high
levels in vivo.
iaRNA
HSF1 is a potent HSF1 antagonist under non-heat
shock conditions
To determine the in vivo efﬁcacy of the iaRNA
HSF1 as a
HSF1 antagonist, we measured its effect on known HSF1
gene targets under both non-heat shock (NHS) and HS
conditions. We focused initially on the Hsp83 gene locus
(63B), which is the ortholog of mammalian Hsp90,
because it is expressed under non-stress inducing condi-
tions, and HSF1 is signiﬁcantly enriched at this locus
compared to other loci (32,33). We investigated the
effects of iaRNA
HSF1 expression at three different levels:
(i) HSF1 binding to the Hsp83 chromosomal locus,
(ii) Hsp83 mRNA levels and (iii) traits in animals.
Antibody staining for HSF1 on Drosophila salivary
gland chromosomes conﬁrms that under normal growth
conditions HSF1 preferentially binds to the Hsp83 gene
locus (63B) [Figure 2B, compare HSF1 signal (red) relative
to GAF control (green)]. However, upon iaRNA
HSF1 ex-
pression, the HSF1 levels at the 63B locus is signiﬁcantly
reduced by  50% (P=0.035) (Figure 2C, left).
Previous reports have implicated the enhancer elements
and upstream regulatory sequences present in the
promoter regions of the Hsp83 gene as being critical for
Hsp83 gene expression (34); however the Hsp83 upstream
region also has a tandem array of nine binding sites for the
HSF DBD. Because, there is currently no direct evidence
indicating whether HSF1 has a role in regulating the basal
expression of Hsp83, we tested whether HSF1 inhibition
compromises Hsp83 expression levels by quantifying the
levels of Hsp83 mRNA in iaRNA
HSF1 expressing and
wild-type (Gal4 parental) animals not exposed to
thermal stress (NHS). In these and the following RT–
qPCR experiments, we determine and compare HS
mRNAs by normalizing their values to a housekeeping
gene whose level does not vary relative to total RNA in
response to HSF1 aptamer expression, HSF1 RNAi treat-
ment, or temperature. Here, animals that express
iaRNA
HSF1 contain an  50% reduction of Hsp83
mRNAs compared to control animals (Figure 2C, right)
(P=0.008), indicating that under non-HS conditions
HSF1 activity is required for the expression of Hsp83.
We conﬁrmed this result using another approach, which
involved RNAi-depletion of HSF1 from Drosophila S2
cells. In these experiments, HSF1 knockdown resembled
the effects of iaRNA
HSF1 expression and similarly
reduced the expression levels of Hsp83 and Hsp70
transcripts (Supplementary Figure S1D), thus further
demonstrating that normal HSF1 activity is required for
the full expression of HS mRNAs under normal growth
conditions.
Adult animals that constitutively express iaRNA
HSF1
display phenotypic abnormalities in the abdominal
segments, wing shape and morphology, bristles and eye
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frequencies (Figure 2D). Intriguingly, the aptamer-
induced phenotypes closely resemble the abnormalities
that occur when Hsp83 activity is reduced; although the
developmental defects occur at much greater frequencies
(35,36). This increased penetrance is best illustrated by
the notched wing phenotype observed in  90% of
iaRNA
HSF1 expressing animals; while this same pheno-
type is only present in  5–20% of the wild-type animals
that have been raised in media containing the Hsp83
inhibitor (17-AAG) during the ﬁrst two generations, and
in <1% of Hsp83
e6D antimorphic mutants. The observed
increased penetrance of abnormal traits that occurs
among aptamer expressing animals might be a result of
inbreeding of ﬂy populations that have such abnormal
traits, as has been shown in previous studies of Hsp83
mutant animals or feeding animals with 17-AAG (36).
Additionally, or alternatively, we cannot rule out HSF1
having some contribution to basal expression of other HS
proteins that are known to contribute to Hsp83’s
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Figure 1. Biochemical characterization of an inhibitory aptamer that targets HSF1, iaRNA
HSF1.( A) Lowest energy diagram predicting the second-
ary structure of the dimeric HSF aptamer (iaRNA
HSF1) using M-fold (upper case=HSF1 aptamer; lower case=self-cleaving hammer head
ribozyme). (B) Electrophoretic motility shift assay (EMSA) using radiolabeled iaRNA
HSF1 (1nM) and increasing amounts of dHSF1 protein
shows that the aptamer RNA binds to its target avidly. (C) Quantiﬁcation of independent EMSA assays reveals the apparent afﬁnity of the
iaRNA
HSF1  Kd=8nM (n=5, error indicates %SEM). (D) iaRNA
HSF competes with HSF1 DNA binding at native promoters in vitro. HSF1
EMSA using limiting amounts of Hsp83 promoter DNA (1nM) ( 449>+114)(lanes 2–12), and increasing molar (M) concentrations of cold
‘non-radiolabeled’ iaRNA
HSF1 (lanes 9–12) or yeast tRNA (lanes 5–8). (E) Quantiﬁcation of competition experiments by ﬁlter binding assays
using Hsp83 ( 449>+114) or Hsp70 ( 200>+64) promoter DNA. Data normalized to highest ytRNA signal (Hsp70 %SEM n=3, Hsp83
%SEM n=6).
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strate that under NHS conditions, iaRNA
HSF1 expression
can compromise HSF1 binding to its native binding sites,
such as the Hsp83 locus (63B), resulting in decreased
Hsp83 transcript levels and giving rise to animals with
phenotypes that resemble loss of function Hsp83
mutants (Figure 2).
iaRNA
HSF1 is a potent HSF1 antagonist under HS
conditions
It is well documented that under HS conditions, HSF1
undergoes homo-trimerization and binds with high
afﬁnity to the HS elements (HSE) of HS promoters
(33,37). HSF1 binding to promoters results in the recruit-
ment of various components of the transcription machin-
ery (38), dramatic changes in chromatin architecture and
nucleosome disruptions over the entire gene locus (39),
and  200-fold increase in expression of major HS genes.
Although iaRNA
HSF1 is predicted to have more difﬁculty
competing against the DNA binding capacity of
HS-activated HSF1 homotrimers, we do observe a
modest but reproducible inhibitory effect. Figure 3A
shows that ﬂy lines that contain 48 dimeric aptamer
repeats (three 16-mer arrays inserts crossed into a single
line) have high-level iaRNA
HSF1X48 expression that is suf-
ﬁcient enough to compromise HSF1 binding to the Hsp70
(87A and C) loci following HS treatment. Quantiﬁcation
of the HSF1 antibody signals, which are normalized to
GAGA factor antibody staining at a nearby site that
does not undergo ‘pufﬁng’ (86E), shows the effectiveness
of the iaRNA
HSF1 at inhibiting the ability of HSF1 to
bind at both the 87A and 87C loci (Figure 3B).
Furthermore, quantiﬁcation of the total mRNAs from
three major classes of HS genes: Hsp26, Hsp70 and
Hsp83 demonstrates that iaRNA
HSF1 expression reduces
their expression (Figure 3C).
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Figure 2. iaRNA
HSF1 is a potent HSF1 antagonist under NHS conditions. (A) Design of iaRNA expression system in vivo. Diagram of a polymeric
template of 16 iaRNA
HSF1 gene units and their corresponding transcripts (i) corresponds to the ﬁrst processed iaRNA
HSF1 which lacks a hammer-
head, (ii) correspond to the middle iaRNA
HSF1 repeats that contain the ‘self-cleaving’ hammer head ribozymes and (iii) corresponds to the ﬁnal
processed hammer head ribozyme that does not have the iaRNA
HSF1.( B) Constitutive iaRNA
HSF1 expression results in decreased HSF1 binding to
Hsp83 gene (63B locus) during non-induced (NHS) conditions (note: the average diameter of a polytene chromosome is 4mm). (C) Quantiﬁcation of
the relative intensities shown in panel B among WT (n=29) and iaRNA
HSF1 expressing animals (n=29) (left), and quantiﬁcation of Hsp83 mRNAs
in WT (n=6) and iaRNA
HSF1 (n=6) expressing animals (right) shows that constitutive iaRNA
HSF1 expression inhibits HSF1 binding to the Hsp83
locus under NHS conditions in vivo (observed signals normalized to GAF intensities at 63A). (D) HSF1 inhibition by iaRNA
HSF1 results in adult
animals that resemble Hsp83 loss-of-function mutants, and in animals that display abnormal animal morphology within abdominal segments, wings
and bristle structures at high frequencies (n >500 animals).
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HSF1–HSF1
interaction
Overexpression of either iaRNA
HSF1 or HSF1 results in
increased lethality and an increased frequency of speciﬁc
morphological phenotypes. To assess the speciﬁcity of
iaRNA
HSF1 for HSF1, we reasoned that overexpression
of both molecules within the same animal should amelior-
ate the aberrant phenotypes of each. This genetic
approach is analogous to factor titration or add-back ex-
periments in biochemical assays, where the inhibition of a
protein by an RNA aptamer is reversed by the addition of
excess protein (22,23,25).
First, we assessed if HSF1 overexpression could
suppress the abnormalities induced by iaRNA
HSF1
overexpression. Here, systemic iaRNA
HSF1 expression
results in lethality that occurs with increasing
iaRNA
HSF1 gene dosage (Figure 4A, compare animals
that express 8, 24 and 48 iaRNA
HSF1 repeats). We
reasoned that the observed lethality that occurs among
animals expressing high levels of iaRNA
HSF1X48 is likely
due to the fact that HSF1 is an essential gene for
Drosophila development (9). This iaRNA
HSF1-induced
effect is effectively suppressed upon HSF1 co-expression
(Figure 4A, compare gray and blue column). Additionally,
we took advantage of the abnormal wing (notching) defect
that occurs with a high frequency in iaRNA
HSF1 express-
ing animals to further determine the speciﬁcity of
iaRNA
HSF1 to HSF1. We choose to focus on the
abnormal (notch) wing phenotype because it occurred
most frequently in the aptamer expressing population,
and as with any genetic suppression analysis, it provided
us with an easily observable phenotype that was quick to
score. Figure 4B shows that the notched wing defect
occurs in iaRNA
HSF1 expressing animals and is absent
in any of the parental stocks (Figure 4B, compare
parental controls). Moreover, this abnormality is not
affected by GFP overexpression, but it is effectively
rescued upon overexpression of either HSF1, or Hsp83,
a major product of HSF1 activity in non-stressed cells
(Figure 4B).
Second (a complementary test), we assayed if
iaRNA
HSF1 expression could suppress the abnormalities
induced by HSF1 overexpression. We ﬁnd that
tissue-speciﬁc HSF1 overexpression results in abnormally
small salivary glands (Figure 4C, compare right and left
panel). This abnormality is effectively suppressed when
iaRNA
HSF1 co-expressed with overexpressed HSF1
(Figure 4C, middle panel). Quantiﬁcation of the salivary
gland length among WT animals and animals that either
overexpress HSF1 alone or with iaRNA
HSF1 shows that
iaRNA
HSF1 co-expression restores the salivary gland
morphology to nearly WT size (Figure 4D).
Furthermore, we ﬁnd that the high frequencies of lethality
in ﬂies with high-level systemic HSF1 overexpression
(Figure 4A) is effectively suppressed by iaRNA
HSF1
co-expression, resulting in viable and fertile animals
(Figure 4A). Lastly, we decided to express the HSF1
aptamer (iaRNA
HSF1) and compare its effects with a
control aptamer RNA (Rev) that lacks the sequence spe-
ciﬁcity to target HSF1 protein in stably selected
Drosophila S2 cells. Placing each aptamer gene under the
control of the copper-inducible promoter results in tight
chemical control and high amounts of aptamer levels upon
addition of low amounts of CuSO4 (Supplementary Figure
S2A). In this system, we observe decreased HSF1 levels at
the Hsp70 promoter upon iaRNA
HSF1, but not control
RNA (Rev) expression (Supplementary Figure S2B).
Moreover, iaRNA
HSF1 expression inhibits CuSO4 induc-
tion of Hsp70 while expression of the control RNA
sequence does not (Supplementary Figure S2C).
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Figure 3. iaRNA
HSF1 expression inhibits HSF1 activity under HS conditions in vivo.( A) High-level iaRNA
HSF1 inhibits HSF1 binding to Hsp70
gene loci under HS conditions (left column=WT, right column=iaRNA
HSF1X48; antibodies: red=HSF1, green=GAF, blue=DNA, dot=87A
locus, triangle=87C locus) (note: the average diameter of a polytene chromosome is 4mm). (B) Quantiﬁcation of the relative ﬂuorescence of HSF1 in
panel E at Hsp70 (87AC loci) among WT or iaRNA
HSF1X48 expressing animals (signals normalized to GAF intensity at 86E locus. WT n=5;
iaRNA
HSF1 n=14). (C) Constitutive iaRNA
HSF1 expressing compromises major HS gene activation by HSF1 during heat stress (mRNAs quantiﬁed
by RT–qPCR. Error %SEM, WT n=4, iaRNA
HSF1 n=4).
Nucleic Acids Research, 2011,Vol.39, No. 15 6735Taken together, we conclude that iaRNA
HSF1 does not
produce its phenotypes non-speciﬁcally, but rather acts
on the intended target, HSF1, thereby inhibiting expres-
sion of Hsp83, which is HSF1’s primary target of binding
and regulation under non-induced conditions.
iaRNA
HSF1 expression attenuates phenotypes of
hyperactive mutations in the MAPK signaling pathway
Hsp83 is known to modulate the MAPK signaling
pathway, a well-conserved and important regulatory
pathway that is frequently overactivated in human
cancers (40). In Drosophila, gain-of-function mutations
within the MAPK pathway does not result in tumor for-
mation; rather, hyper-activation of the MAPK pathway
results in an altered cell fate speciﬁcation and abnormal
tissue morphology. Components of this pathway, such as
the EGFR and Raf oncogenes, depend on normal levels of
Hsp83 activity for their proper folding, localization or
kinase activity (1,41). Thus, the inhibitory potential of
the aptamer on the MAPK pathway can be analyzed
in vivo by comparing the effects of iaRNA
HSF1 expression
in animals that also harbor gain-of-function EGFR
(ellipse) or Raf (Raf
BT98) mutations. Here, tissues that
have decreased MAPK signaling activity should more
closely resemble the tissues of animals that do not
harbor the gain-of-function mutants.
Expression of iaRNA
HSF1 inhibits HSF1 and this, in
turn, decreases Hsp83 levels. Because Hsp83 is needed
for MAP kinase pathway function, we sought to deter-
mine if iaRNA
HSF1 expression might suppresses the
abnormalities induced by gain-of-function mutations of
the Drosophila EGFR
ellipse and Raf
BT98 oncogenes.
Heterozygote animals that express EGFR
ellipse have been
previously shown to contain abnormal wing veins morph-
ology (42). Indeed, this abnormality is effectively
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Figure 4. iaRNA
HSF1 inhibits HSF1 with high speciﬁcity in vivo.( A) Co-expression of iaRNA
HSF1 and HSF1 suppress the lethality induced by either
high-level iaRNA
HSF1 or HSF1 overexpression. (B) HSF1 and Hsp83 overexpression, but not GFP overexpression, completely suppresses the
notched wing phenotype induced by high-level iaRNA
HSF1 expression [WT parental controls: (F0) UAS.iaRNA
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iaRNA
HSF1 expressing animals with notched wings (F1: iaRNA
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HSF1+GFP), iaRNA
HSF1 expressing animals with an additional copy of Hsp83 gene (F1: iaRNA
HSF1+Hsp83), and animals that
overexpress iaRNA
HSF1 and HSF1 protein (F1: iaRNA
HSF1+HSF1) (n>500 animals). (C) iaRNA
HSF1 suppresses the adverse effects of HSF1
overexpression in the Drosophila salivary glands (left=overexpress HSF1
GFP; middle=overexpress HSF1
GFP+iaRNA; right=WT).
(D) Quantiﬁcation of salivary gland length of panel C (error %SEM, WT n=9; HSF1
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HSF1,o r
when Hsp83 activity is compromised by expression of
the Hsp83
e6D antimorphic mutant or when EGFR
ellipse
hemizygote ﬂies are treated with the Hsp90 inhibitor
17-AAG (Figure 5A).
Similarly, heterozygote animals that express a
gain-of-function Raf
BT98 protein have been shown to
contain multiple cells within each ommatidium resulting
in ﬂies with a distinct rough eye morphology (Figure 5B).
Moreover, it has been previously demonstrated that
Raf
BT98 mutants require normal Hsp83 activity to exert
this eye speciﬁc defect (41). In agreement with the previous
ﬁndings, we ﬁnd that the rough eye phenotype that is
induced by Raf
BT98 expression can be reversed by
reducing Hsp83 activity through the co-expression of the
Hsp83
e6D antimorphic mutant, or by treating Raf
BT98
animals with 17-AAG (Figure 5B). Consistent with our
ﬁndings that HSF1 controls the expression of Hsp83, we
ﬁnd that HSF1 inhibition by the aptamer also results in
the strong suppression of the rough eye phenotype that is
caused by increased Raf
BT98 signaling activity (Figure 5B).
The affected surface area of the eye with a rough eye
phenotype in each of these overactive MAPK signaling
genetic backgrounds can be effectively attenuated by
iaRNA
HSF1 expression or direct Hsp83 inhibition
(Figure 5C).
DISCUSSION
iaRNA
HSF1 is a novel HSF1 DNA binding domain
inhibitor in vitro and in vivo
In this study, we describe the in vivo utility of an aptamer
that targets the highly conserved HSF1 DNA binding
domain. We engineered a potent inhibitor of trimeric
HSF1 by constructing a dimeric molecule derived from
two copies of a previously selected RNA aptamer, which
had a modest Kd of  20–30nM. The dimeric aptamer
(iaRNA
HSF1) binds HSF1 with an improved afﬁnity of
Kd of  8nM. By creating a genetically controlled expres-
sion system, which contains polymers of a dimeric
aptamer fused to a self-cleaving ribozyme, we demonstrate
that we can express iaRNA
HSF1 at high levels in whole
animals. In cells, this RNA molecule displays an
in vivo half-life of 2–4h, is adequate to produce the
phenotypes in animals seen here. Moreover, it can be a
useful inhibitor particularly in basic studies of the HS
response that are often performed within the ﬁrst few
hours following stress induction. We do, however, ac-
knowledge that the effectiveness of the aptamer could
beneﬁt from other modiﬁcations that further limit exo-
nuclease degradation.
It is well-documented that HS stress can affect the
monomer–oligomer equilibrium status of HSF1 (43).
Within seconds following a heat stress, HSF1 shifts from
a monomer to a homotrimer state, binding stably and
cooperatively to HS gene promoters (37). This can be
visualized in vivo using real-time imaging techniques;
under normal growth conditions, where monomeric
HSF1 displays rapid off-rates with its target genes, but
is stably associated with target loci after the cells have
been exposed to heat stress (33). Here, we show that our
HSF1 aptamer can prevent HSF1 binding to HS loci and
its ability to induce gene expression under both normal
and stress conditions in vivo. While the aptamer is effective
in inhibiting the modest HSF1 DNA binding activity in
NHS cells, it only partially inhibits strong HSF1 binding
B
A
C WT (iaRNA) RafBT98
WT (Tub.Gal4) RafBT98 +Hsp83e6D
RafBT98 + iaRNA
WT                        EGFREllipse EGFREllipse+ iaRNA RNA
iaRNA EGFREllipse+ Hsp83e6D EGFREllipse+ 17AAG
RafBT98+ 17AAG
Figure 5. Expression of iaRNA
HSF1 suppresses gain-of-function mutations of genes in the MAPK signaling pathway. (A) iaRNA
HSF1 expression and
Hsp83 inhibition suppress the abnormal wing phenotype induced by the EGFr
Elp mutant. (B) iaRNA
HSF1 expression and Hsp83 inhibition suppress
the rough eye phenotype induced by activated Raf
BT98 mutant. (C) Quantiﬁcation of rough eye phenotypes in panel B calculated by area. Error
%SEM, WT (n=5); Raf
BT98 (n=26); Raf
BT98+iaRNA
HSF1 (n=33); Raf
BT98+Hsp83
e6D (n=33); Raf
BT98+3.6mM 17AAG (n=33).
Nucleic Acids Research, 2011,Vol.39, No. 15 6737in HS cells (Figure 3). We note that aptamer expressing
animals show normal survival after heat stress, pre-
sumably because the levels of chaperone expression is suf-
ﬁcient to overcome the proteotoxic effects of heat.
However, high-level expression of this aptamer in yeast
cells results in strong growth defects at elevated tempera-
tures (44).
Whenever a ligand such as an aptamer is used in vivo to
study and manipulate the function of a protein, it is im-
portant to know whether the intended target is speciﬁcally
recognized by the ligand/drug. However, testing the
binding of iaRNA
HSF1 to every protein in a cell is not
feasible. Instead, we use functional assays to demonstrate
that effect of iaRNA
HSF1 is speciﬁc to HSF1. The
abnormalities that arise from the expression of
iaRNA
HSF1 in Drosophila are effectively suppressed by
HSF1 co-expression and not a control protein like GFP,
suggesting that the aptamer is exerting its effects by tar-
geting HSF1
25. Conversely, the abnormalities observed in
Drosophila induced by HSF1 overexpression are also
effectively suppressed by iaRNA
HSF1 overexpression.
Moreover, in Drosophila S2 cells iaRNA
HSF1 expression
effectively attenuates HSF1 activity while expression of a
control aptamer sequence (Rev) does not. Collectively,
our analysis provides further supporting evidence for the
speciﬁc nature of the aptamer–HSF1 interaction in vivo.
HSF1 regulates the activity of the Hsp83 (Hsp90)
buffering system that promotes adaptation to stress
In contrast to mammals, where the Hsp83 locus (Hsp90) is
not controlled by HSF1 but rather by other HSF isoforms
(45), here we show that Drosophila, which has a single
of HSF gene, requires HSF1 for the proper expression
of Hsp83 during development. The constitutive level of
Hsp83 protein is impressive, reaching concentrations of
1–2% of the total protein content in vivo (45–47). This
HSF1 involvement in constitutive expression of Hsp83
was ﬁrst suggested by the fact that the Hsp83 locus (cyto-
logical site 63B) shows the highest HSF1 occupancy over
any site on Drosophila chromosomes. We also ﬁnd that
either iaRNA
HSF1 or HSF1 RNAi expression in
Drosophila reduces the levels of HS transcripts, and in
particular, the constitutive levels of Hsp83. Hsp83 has a
general role in biological processes such as spermatogen-
esis, protein trafﬁcking, signal transduction, cytoskelletal
organization and cell survival pathways (41,48–52). Given
the fact that Hsp83 exerts its chaperone functions in
concert with other HS proteins; it is, therefore, likely
that decreasing various HS mRNAs levels with
iaRNA
HSF1 expression attenuates Hsp83 activity resulting
in animals that have phenotypes of previously reported
Hsp83 mutants (35), albeit at much higher frequencies
than seen previously in Hsp83 hemizygotes. Moreover,
we ﬁnd that iaRNA
HSF1 expression effectively attenuates
the abnormal activities of Hsp83 client proteins, EGFR
and Raf oncoproteins. Collectively, our data suggest that
in Drosophila the Hsp83 gene is a primary target of HSF1
regulation during normal conditions, and is highly respon-
sive to HSF1 inhibition during animal development.
This study builds upon a previous Hsp83-directed
chaparone ‘buffering’ model (35,36), and our data
supports the hypothesis that the master regulator HSF1
is critical for constitutive expression of molecular chaper-
ones. In particular, HSF1 inhibition results in an altered
chaperone-driven buffering system that promotes animal
trait variation and the signaling activities of cancer
causing mutations (Supplementary Figure S3). Herein,
we provide an in vivo approach aimed at understanding
HSF1 function during animal development and its
putative role for early drug target validation. Because
the HSF1 DNA-Linker domain is highly conserved
among eukaryotes (53), it is likely that this novel HSF1
inhibitor (iaRNA
HSF1), or derivatives thereof will prove to
be a useful reagent(s) that will further aid in unraveling the
functions of related HS transcription factors in other
model organisms or of HSF1-dependent diseases such as
cancer.
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